ICER Will Explore Link Between Reasonable Drug Pricing And ‘Fair’ US Formulary Policies
Executive Summary
Study will examine prior authorization and other access restrictions at 15 of the largest US commercial payers for a group of 27 drugs.
You may also be interested in...
Cigna Switch Program Intensifies Competitive Dynamics For Cosentyx
A new pilot program by the insurer is offering a $500 debit card to patients who switch from the blockbuster Novartis psoriasis drug to Lilly's rival Taltz or other preferred drugs.
DTC Ads Might Inflate Medicare Drug Spending But Clear Cause-And-Effect Is Elusive, GAO Concludes
Sens. Durbin and Grassley hope report will help revive their flagging legislation that would require Rx ads to include list prices Senators claim that the Government Accountability Office concludes that direct-to-consumer spots for prescription drugs drives ‘drastic’ increases in Medicare costs.
Medicaid Programs Should Be Able To ‘Compel’ Value-Based Contracts, State Association Official Says
Existing value-based contracts, which are voluntary for manufacturers, do not lower costs for states, National Association of Medicaid Directors executive director Matt Salo suggests.